[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506821":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":211,"collaborators":11,"id":213,"slug":11,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":11,"eligibilityCriteria":218,"healthyVolunteers":214,"sex":219,"minAge":220,"maxAge":11,"enrollmentInfo":221,"targetDuration":11,"studyType":224,"phases":225,"briefSummary":227,"conditions":228,"keywords":11,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},{"fullName":5,"class":6},"Orbus Therapeutics, Inc.","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Eflornithine Dose Level 1 + Temozolomide","EXPERIMENTAL",null,[13,14],"Drug: Eflornithine (Dose Level 1)","Drug: Temozolomide",{"label":16,"type":10,"description":11,"interventionNames":17},"Eflornithine Dose Level 2 + Temozolomide",[18,14],"Drug: Eflornithine (Dose Level 2)",{"label":20,"type":10,"description":11,"interventionNames":21},"Eflornithine Dose Level -1 + Temozolomide",[22,14],"Drug: Eflornithine (Dose Level -1)",[24,31,36,41],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Eflornithine (Dose Level 1)","Eflornithine 2.3 g\u002Fm2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",[9],[30],"DFMO",{"type":25,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Eflornithine (Dose Level 2)","Eflornithine 2.8 g\u002Fm2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",[16],[30],{"type":25,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Eflornithine (Dose Level -1)","Eflornithine 1.75 g\u002Fm2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule",[20],[30],{"type":25,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Temozolomide","Temozolomide 150 mg\u002Fm2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule",[20,9,16],[46,47],"Temodar","TMZ",[49],{"name":50,"affiliation":51,"role":52},"Howard Colman, MD, PhD","Huntsman Cancer Institute\u002F University of Utah","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"Monika Varga","CONTACT","6506569424","monika.varga@orbustherapeutics.com",[60,73,95,114,131,150,171,191],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":11},"University of Alabama at Birmingham","WITHDRAWN","Birmingham","Alabama","35294","United States",{"type":68,"coordinates":69},"Point",[70,71],-86.80249,33.52066,{"lat":71,"lon":70},{"facility":74,"status":75,"city":76,"state":77,"zip":78,"country":66,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Henry Ford Hospital","RECRUITING","Detroit","Michigan","48202",{"type":68,"coordinates":80},[81,82],-83.04575,42.33143,{"lat":82,"lon":81},[85,89,93],{"name":86,"role":56,"phone":87,"phoneExt":11,"email":88},"Meghan Gauronskas","313-725-7871","mgauron1@hfhs.org",{"name":90,"role":56,"phone":91,"phoneExt":11,"email":92},"Angela Dunn","313-725-7870","adunn6@hfhs.org",{"name":94,"role":52,"phone":11,"phoneExt":11,"email":11},"Tobias Walbert, MD, PhD, MPH",{"facility":96,"status":75,"city":97,"state":97,"zip":98,"country":66,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Columbia University Medical Center - Herbert Irving Pavilion","New York","10032",{"type":68,"coordinates":100},[101,102],-74.00597,40.71427,{"lat":102,"lon":101},[105,109,113],{"name":106,"role":56,"phone":107,"phoneExt":11,"email":108},"Maria Diaz, MD","212-342-0571","md4157@cumc.columbia.edu",{"name":110,"role":56,"phone":111,"phoneExt":11,"email":112},"Nurse Navigators","212-342-5162","cancerclinicaltrials@cumc.columbia.edu",{"name":106,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":115,"status":75,"city":116,"state":117,"zip":118,"country":66,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Duke University","Durham","North Carolina","27710",{"type":68,"coordinates":120},[121,122],-78.89862,35.99403,{"lat":122,"lon":121},[125,129],{"name":126,"role":56,"phone":127,"phoneExt":11,"email":128},"Erin Severance","919-668-6230","erin.k.bell@duke.edu",{"name":130,"role":52,"phone":11,"phoneExt":11,"email":11},"Annick Desjardins, MD, FRCPC",{"facility":132,"status":75,"city":133,"state":134,"zip":135,"country":66,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"The Cleveland Clinic","Cleveland","Ohio","44195",{"type":68,"coordinates":137},[138,139],-81.69541,41.4995,{"lat":139,"lon":138},[142,146,149],{"name":143,"role":56,"phone":144,"phoneExt":11,"email":145},"David Peereboom, MD","216-445-6068","peerebd@ccf.org",{"name":147,"role":56,"phone":11,"phoneExt":11,"email":148},"Rachel Hufsey, RN","hufseyr@ccf.org",{"name":143,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":151,"status":75,"city":152,"state":153,"zip":154,"country":66,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Brown University Health\u002FRhode Island Hospital","Providence","Rhode Island","02903",{"type":68,"coordinates":156},[157,158],-71.41283,41.82399,{"lat":158,"lon":157},[161,165,169],{"name":162,"role":56,"phone":163,"phoneExt":11,"email":164},"Nuno Rodrigues, RN","401.444.3059","Nuno.Rodrigues@brownhealth.org",{"name":166,"role":56,"phone":167,"phoneExt":11,"email":168},"Gada Alam","401-444-6217","GAlam@brownhealth.org",{"name":170,"role":52,"phone":11,"phoneExt":11,"email":11},"Eric Wong, MD",{"facility":172,"status":75,"city":173,"state":174,"zip":175,"country":66,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"UT MD Anderson Cancer Center","Houston","Texas","77030",{"type":68,"coordinates":177},[178,179],-95.36327,29.76328,{"lat":179,"lon":178},[182,186,190],{"name":183,"role":56,"phone":184,"phoneExt":11,"email":185},"Carlos Kamiya Matsuoka, MD","713-408-3538","CKamiya@mdanderson.org",{"name":187,"role":56,"phone":188,"phoneExt":11,"email":189},"Evguenia Gachimova, RN","832-266-3519","Egachimova@mdanderson.org",{"name":183,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":192,"status":75,"city":193,"state":194,"zip":195,"country":66,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"University of Utah, Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":68,"coordinates":197},[198,199],-111.89105,40.76078,{"lat":199,"lon":198},[202,206,210],{"name":203,"role":56,"phone":204,"phoneExt":11,"email":205},"Rachel Kingsford","801-585-0115","rachel.kingsford@hci.utah.edu",{"name":207,"role":56,"phone":208,"phoneExt":11,"email":209},"Yuri Kida","801-646-4397","yuri.kida@hci.utah.edu",{"name":50,"role":52,"phone":11,"phoneExt":11,"email":11},{"type":212,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100506821",false,"NCT05879367","Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","Inclusion Criteria:\n\n* Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A\u002FB intact) per WHO 2021 tumor classification.\n* Completed external beam radiation therapy per standard of care.\n* Patients with GBM: Must have received at least 80% of planned daily doses of TMZ during chemoradiation. Patients with astrocytoma: Must have tolerated adjuvant TMZ treatment through at least 2 and not more than 4 cycles.\n* Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.\n* Willing to abstain from intercourse or use acceptable contraceptive methods.\n* If taking corticosteroids, must be on a stable or decreasing dose.\n\nExclusion Criteria:\n\n* Recent history of recurrent or metastatic cancer that could confound response assessments\n* Prior systemic chemotherapy other than temozolomide during external beam radiation therapy (for patients with GBM) or adjuvant temozolomide through up to 4 pre-study cycles (for patients with astrocytoma).\n* Prior Optune treatment.\n* Active infection or serious intercurrent medical illness.\n* Poorly controlled seizures.\n* Significant cardiac disease within 6 months of enrollment.\n* Poorly controlled diabetes.\n* Use of another investigational agent within 30 days of enrollment.","ALL","18 Years",{"count":222,"type":223},66,"ESTIMATED","INTERVENTIONAL",[226],"PHASE1","The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.",[229,230,231,232,233,234,235],"Glioblastoma, IDH-wildtype","Glioblastoma","Glioblastoma Multiforme","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","GBM","Astrocytoma","Astrocytoma, IDH-Mutant","2025-06-19",{"date":238,"type":239},"2025-06-25","ACTUAL",{"date":241,"type":239},"2023-07-24",{"date":243,"type":223},"2026-06-30",{"name":5,"class":6},8]